Axe provides an AI-powered procurement assistant, Mia, that automates manual back-office tasks such as purchase requests, approvals, and contract renewals through a chat interface. By consolidating supplier information and enforcing compliance, Mia enhances visibility into company spending and reduces operational inefficiencies, resulting in significant cost savings for businesses.

GenEdit utilizes the NanoGalaxy® delivery platform to enhance the safe and efficient delivery of CRISPR-Cas9 gene editing therapies for genetic diseases. This technology addresses the challenge of limited access to effective genetic medicines, enabling broader patient treatment options.

Ned offers a white-label platform that automates the lending process for small businesses by providing real-time cash flow underwriting and customizable repayment structures, including fixed and revenue-based loans. This technology enables lenders to efficiently qualify borrowers with limited credit history, streamline disbursement, and monitor loan performance, ultimately enhancing capital deployment and reducing default risks.

Noa Therapeutics is developing non-steroidal, multimodal small molecules that target three distinct drivers of inflammatory barrier diseases, utilizing a computer-assisted drug discovery engine. This approach aims to improve treatment efficacy and safety for conditions like atopic dermatitis, addressing the limitations of current therapies that primarily focus on symptom relief.

Pasqal develops programmable quantum simulators and quantum computers using neutral atoms trapped in optical tweezers, enabling the realization of superposition and entanglement for quantum information processing. This technology addresses the limitations of classical computing by providing scalable solutions for complex problem-solving across various industries, including finance, healthcare, and energy.

Proteinea employs proprietary AI models and computational tools to engineer next-generation antibodies, enhancing their efficacy, safety, and convenience for therapeutic applications. The platform addresses the challenges of traditional protein engineering by optimizing protein characteristics and accelerating lead validation through a combination of advanced computational and experimental methods.

Renewal Bio develops synthetic embryo models derived from pluripotent stem cells to study early human development. The company utilizes advanced stem cell biology to generate in vitro models that mimic post-implantation stages of embryogenesis. This platform aims to advance understanding of human biology and developmental processes.